Updates

June 20, 2026 BSE Limited National Stock Exchange of India Ltd Listing Department- Exchange Plaza, C-1, Block G, Phiroze Jeejeebhoy Tower, Bandra Kurla Complex, Dalal Street, Bandra (E) Mumbai – 400 001, Mumbai – 400 051, Scrip Code- 533543, Symbol: BROOKS Dear Madam/ Sir, Subject: Submission of additional details sought for Corporate Announcement submitted under Regulation 30 of SEBI (LODR) Regulations, 2015 Reference: Corporate Action - “Partial Sale Of Equity Shares Held In Brooks Steriscience Limited” submitted on 19th June 2026 With reference to corporate announcement titled “Partial Sale of Equity Shares Held In Brooks Steriscience Limited” submitted by company on 19th June 2026, we wish to inform you that the Company has received an email from BSE Limited seeking additional details, specifically the Board Meeting commencement and conclusion time, in compliance with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024. Accordingly, we hereby submit the revised disclosure and provide the following update: • Board Meeting Commencement Time: 16:00 hours • Board Meeting Conclusion Time: 19:30 hours We request you to kindly take the above information on record. Thanking You. For Brooks Laboratories Limited, Krutika Rane Company Secretary and Compliance Office Membership No.: 66310 June 20, 2026 BSE Limited National Stock Exchange of India Ltd Listing Department- Exchange Plaza, C-1, Block G, Phiroze Jeejeebhoy Tower, Bandra Kurla Complex, Dalal Street, Bandra (E) Mumbai – 400 001, Mumbai – 400 051, Scrip Code- 533543, Symbol: BROOKS Dear Madam/ Sir, Sub: Sale of Equity Shares held in Brooks Steriscience Limited. Pursuant to Regula�on 30 read with Schedule III of the SEBI (Lis�ng Obliga�ons and Disclosure Requirements) Regula�ons, 2015 ("SEBI Lis�ng Regula�ons"), we hereby inform that the Board of Directors of the Company, at its mee�ng held today i.e. 19th June 2026, has approved the sale of 51,220 (Fi�y-One Thousand Two Hundred and Twenty) Equity Shares held by the Company in Brooks Steriscience Limited to Steriscience Special�es Private Limited for a cash considera�on of ₹20,760 per share aggrega�ng to approximately ₹106.33 crore, subject to comple�on of customary documenta�on and applicable regulatory requirements. The transac�on represents a par�al mone�za�on of the Company's investment in Brooks Steriscience Limited and does not cons�tute a complete divestment. Upon comple�on of the transac�on, the Company will con�nue to hold 1,02,440 Equity Shares, represen�ng 32.67% of the paid-up share capital of Brooks Steriscience Limited. The details as required under Regula�on 30 of the SEBI Lis�ng Regula�ons read with SEBI Master Circular No. SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are provided below in Annexure 1 The Board meeting commenced at 16:00 hrs and concluded at 19:30 hrs. You are requested to kindly take the same in record. Thanking You. For Brooks Laboratories Limited, Krutika Rane Company Secretary and Compliance Office Membership No.: 66310 Annexure A Details under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026: Sr. No. Particulars Details 1 Name of the entity whose shares are to Brooks Steriscience Limited be transferred 2 Whether the acquisition/disposal would No fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being disposed of 3. Object and effects of disposal The proceeds received from the transaction will be deployed towards the Company's growth strategy, including expansion of operations, capacity enhancement, funding of business opportunities and general corporate purposes. 4. Details of consideration received to be 51,220 equity shares at a cash received per share consideration of ₹20,760 per share, amounting to ₹106,33,27,200 (Rupees One Hundred Six Crore Thirty-Three Lakh Twenty-Seven Thousand Two Hundred only). 5. Percentage of shareholding disposed of 16.33 % representing 51,220 Equity Shares 6. Brief details of the shareholding before Before: 49.00% and After: 32.67% and after disposal 7. Date of approval of the transaction 19th June 2026 8. Any other significant information The transaction shall be completed in accordance with applicable laws and regulations.